TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15071151

Group type: EXPERIMENTAL
Intervention: Fluoridated elastomers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-fluoridated elastomers
Number of subjects: 30
Study: 11414344

Group type: EXPERIMENTAL
Intervention: DWI school plus MADD VIP
Number of subjects: 813

Group type: COMPARATOR
Intervention: DWI school
Number of subjects: 813
Study: 10453590

Group type: EXPERIMENTAL
Intervention: Tang Shen Ning (TSN) + western medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tang Shen Ning (TSN)
Number of subjects: 0
Study: 7881702

Group type: EXPERIMENTAL
Intervention: Calcium-heparin (12,500 IU once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (300 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium-heparin
Number of subjects: 60

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 60
Study: 3108922

Group type: EXPERIMENTAL
Intervention: 1.5‐5 mg haloperidol orally and/or intravenously
Number of subjects: 9
Study: 31926142

Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Therapy (VRBT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 27
Study: 30656509

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.2 mg/mL for 2 min before surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bevacizumab-methylcellulose mixture (BMM) 1.25 mg in 2% methylcellulose injected subconjunctivally after surgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both MMC and BMM
Number of subjects: 38
Study: 27492421

Group type: EXPERIMENTAL
Intervention: Positive chat condition
Number of subjects: 301

Group type: COMPARATOR
Intervention: Negative chat condition
Number of subjects: 301

Group type: COMPARATOR
Intervention: Natural chat condition
Number of subjects: 301
Study: 25376972

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB) with ropivacaine 0.2% 30 mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB) with ropivacaine 0.2% 30 mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 23657413

Group type: EXPERIMENTAL
Intervention: Corega Brite combined with Oral Balance (artificial saliva)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Corega Brite denture dentifrice
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Neutral liquid soap
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 23
Study: 21673483

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) diet
Number of subjects: 221

Group type: COMPARATOR
Intervention: Higher carbohydrate (HC) diet
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Exercise + HP diet in HH group
Number of subjects: 221

Group type: COMPARATOR
Intervention: Exercise + HC diet in HH group
Number of subjects: 221
Study: 19892673

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 17106661

Group type: EXPERIMENTAL
Intervention: Spa therapy (daily local mud packs and arsenical ferruginous mineral bath water) for 3 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Short wave therapy for 3 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional therapy (routine ambulatory care)
Number of subjects: 74
Study: 14633141

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1 g twice daily 24 hours before and after angiography
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 53
Study: 10860688

Group type: EXPERIMENTAL
Intervention: Catheter coated with hydrogel and silver salts (group 2)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Classical catheter (group 1)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 199
Study: 9187790

Group type: EXPERIMENTAL
Intervention: Heat conservation with reflective blankets and warmed i.v. fluids
Number of subjects: 37

Group type: COMPARATOR
Intervention: Convective warming with BairHugger and i.v. fluids at room temperature
Number of subjects: 37
Study: 1493134

Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 38
Study: 3549393

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Booster dose of PRP-D
Number of subjects: 1400

Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 1400
Study: 30637727

Group type: EXPERIMENTAL
Intervention: Emollient cream treatment on upper back
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated sites exposed to water)
Number of subjects: 0
Study: 30341986

Group type: EXPERIMENTAL
Intervention: Four serial phlebotomy procedures followed by intravenous infusion of placebo normal saline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Four serial phlebotomy procedures followed by intravenous infusion to replete lost iron
Number of subjects: 84

Group type: COMPARATOR
Intervention: Four serial sham phlebotomy procedures followed by intravenous infusion of placebo normal saline
Number of subjects: 84
Study: 26819282

Group type: EXPERIMENTAL
Intervention: risperidone (n=13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: zuclopenthixol (n=9)
Number of subjects: 25
Study: 24745839

Group type: EXPERIMENTAL
Intervention: Benzocaine spray
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline spray)
Number of subjects: 30
Study: 22796139

Group type: EXPERIMENTAL
Intervention: VAX128 vaccine (various constructs)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: VAX128C (1.25 μg and 2.5 μg doses)
Number of subjects: 212

Group type: COMPARATOR
Intervention: VAX128A (up to 8 μg)
Number of subjects: 212

Group type: COMPARATOR
Intervention: VAX128B (up to 16 μg)
Number of subjects: 212

Group type: COMPARATOR
Intervention: VAX128C (up to 20 μg)
Number of subjects: 212
Study: 20430328

Group type: EXPERIMENTAL
Intervention: Low-dose BoNT‐A (100 units)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular corticosteroid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose BoNT‐A (200 units)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 60
Study: 18492675

Group type: EXPERIMENTAL
Intervention: Sock with nanocapsules containing a hydrating agent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Socks without nanocapsules
Number of subjects: 30
Study: 15968657

Group type: EXPERIMENTAL
Intervention: Inhalation of carbogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breathing of air
Number of subjects: 0
Study: 12364991

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 30
Study: 10916802

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (AECI)
Number of subjects: 0
Study: 8968479

Group type: EXPERIMENTAL
Intervention: Alcohol (mean BAC = 0.038%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1562290

Group type: EXPERIMENTAL
Intervention: Thyroid hormone triiodothyronine (T3) 30 micrograms/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Extended arctic winter field operations (EAO)
Number of subjects: 27
Study: 3910057

Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg bid)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ranitidine (150 mg bid)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (one tab bid)
Number of subjects: 6
Study: 31402402

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 0
Study: 29979837

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Inhaled anesthesia (IA)
Number of subjects: 72
Study: 25936739

Group type: EXPERIMENTAL
Intervention: u-healthcare group
Number of subjects: 100

Group type: COMPARATOR
Intervention: SMBG group
Number of subjects: 100
Study: 25317806

Group type: EXPERIMENTAL
Intervention: Percutaneous sacroiliac screw internal fixation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sacroiliac anterior plate fixation
Number of subjects: 64
Study: 22313788

Group type: EXPERIMENTAL
Intervention: Atomoxetine plus buspirone (n = 97)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n = 97)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo (n = 47)
Number of subjects: 241
Study: 20819319

Group type: EXPERIMENTAL
Intervention: Oral olopatadine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 18046057

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous cycling (C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cycling with 3‐min rest (R)
Number of subjects: 12
Study: 16287395

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure plus Cognitive Restructuring (PE/CR)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 171
Study: 11676576

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (TG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study: 9158048

Group type: EXPERIMENTAL
Intervention: 60 mg/kg of praziquantel in two divided doses administered 6 hr apart at Farshout
Number of subjects: 1588

Group type: COMPARATOR
Intervention: 40 mg/kg of praziquantel in a single dose at Om El‐Laban
Number of subjects: 1588
Study: 7954027

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 50 mg/kg intravenously
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2852919

Group type: EXPERIMENTAL
Intervention: 1 MU/m2
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 3 MU/m2
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 3 MU/m2 (additional group)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 107
Study: 2164655

Group type: EXPERIMENTAL
Intervention: IVIG, 500 mg/kg
Number of subjects: 91

Group type: COMPARATOR
Intervention: 5% albumin-normal saline (placebo), 10 ml/kg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 999210

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 30
Study: 30795705

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg once daily (OD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 µg twice daily (BD)
Number of subjects: 0
Study: 30044537

Group type: EXPERIMENTAL
Intervention: Baseline SD of IPFP signal intensity
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: High tertile of clustering-factorH
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Medium tertile of clustering-factorH
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Baseline percentageH and clustering-factorH
Number of subjects: 261
Study: 28088032

Group type: EXPERIMENTAL
Intervention: Oral cannabidiol (200mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral cannabidiol (400mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral cannabidiol (800mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Active smoked marijuana (5.3-5.8% THC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 31
Study: 25795645

Group type: EXPERIMENTAL
Intervention: TIA/stroke electronic decision support guided management
Number of subjects: 291
Study: 23827378

Group type: EXPERIMENTAL
Intervention: Enhanced Mother-Infant Transaction Program (PremieStart)
Number of subjects: 123
Study: 21675323

Group type: EXPERIMENTAL
Intervention: Project SUCCESS (substance use prevention program)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Project SUCCESS
Number of subjects: 14
Study: 19832769

Group type: EXPERIMENTAL
Intervention: Ball attachment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Magnetic attachment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study: 16740865

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 127

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 127
Study: 15312254

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 3469

Group type: EXPERIMENTAL
Intervention: Statin use for more than 365 days
Number of subjects: 3469

Group type: COMPARATOR
Intervention: Pravastatin and nonstatin cholesterol-lowering drugs
Number of subjects: 3469
Study: 11684823

Group type: EXPERIMENTAL
Intervention: True acupuncture at LI-4 (colonic meridian, needle only)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham acupuncture at BL-60 (urinary vesicle meridian, needle only)
Number of subjects: 25
Study: 9401510

Group type: EXPERIMENTAL
Intervention: Moisture-problem schools
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Moisture-indicative moulds
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Skin-prick tests for moulds
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reference school
Number of subjects: 133
Study: 8395176

Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crest toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate (Peridex)
Number of subjects: 0
Study: 3121718

Group type: EXPERIMENTAL
Intervention: Phenelzine, L-tryptophan, and lithium ('5HT-cocktail')
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive behaviour therapy
Number of subjects: 20
Study: 30104317

Group type: EXPERIMENTAL
Intervention: Screening test combining fetal cerebroplacental ratio (CPR) and maternal serum placental growth factor (PlGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening test (control)
Number of subjects: 0
Study: 26995280

Group type: EXPERIMENTAL
Intervention: Culturally-adapted intervention (Diabetes Prevention Program)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Culturally-adapted intervention
Number of subjects: 186
Study: 25262271

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (PA) intervention
Number of subjects: 424

Group type: COMPARATOR
Intervention: Education-based 'successful aging' health program
Number of subjects: 424
Study: 23880161

Group type: EXPERIMENTAL
Intervention: Dry polyester‐tipped swab
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Dry foam swab
Number of subjects: 450

Group type: COMPARATOR
Intervention: Emery paper and wetted polyester‐tipped swab
Number of subjects: 450
Study: 20522984

Group type: EXPERIMENTAL
Intervention: Morning administration of rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evening administration of rosuvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who forgot to take rosuvastatin
Number of subjects: 0
Study: 18185500

Group type: EXPERIMENTAL
Intervention: 0, 2.5, and 5 mg intravenous Delta‐9‐THC
Number of subjects: 52
Study: 16357287

Group type: COMPARATOR
Intervention: Control diet (44% forage and 56% concentrate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet supplemented with 2.7% Ca‐PFO (FO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet with 5% extruded full‐fat soybeans + 2.7% Ca‐PFO (FOESM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet with 0.75% soybean oil + 2.7% Ca‐PFO (FOSO)
Number of subjects: 20
Study: 12599080

Group type: EXPERIMENTAL
Intervention: E5564 (50-250 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E5564 (>=100 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E5564
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11421517

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biofeedback (BF)
Number of subjects: 40
Study: 9366328

Group type: COMPARATOR
Intervention: Active device
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dummy device
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Investigational study
Number of subjects: 44
Study: 8115729

Group type: EXPERIMENTAL
Intervention: 660 ng transforming growth factor‐beta 2
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1,330 ng transforming growth factor‐beta 2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Crossover to 1,330 ng transforming growth factor‐beta 2
Number of subjects: 90
Study: 3655000

Group type: EXPERIMENTAL
Intervention: 3-g q4h regimen of azlocillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-g q8h regimen of azlocillin
Number of subjects: 0
Study: 30521063

Group type: EXPERIMENTAL
Intervention: ADT+AA+P
Number of subjects: 1199
Study: 26203099

Group type: EXPERIMENTAL
Intervention: 5.0 g agave inulin/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 7.5 g agave inulin/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Agave inulin (5.0 g and 7.5 g)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Agave inulin (g/kcal)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (including agave inulin)
Number of subjects: 29
Study: 23697723

Group type: EXPERIMENTAL
Intervention: Neuromuscular stretching with symmetrical rectangular biphasic currents
Number of subjects: 34
Study: 20490803

Group type: COMPARATOR
Intervention: Standard care by primary care physicians (PCP)
Number of subjects: 3311

Group type: EXPERIMENTAL
Intervention: Rheumatologists
Number of subjects: 3311
Study: 19309493

Group type: EXPERIMENTAL
Intervention: STAR Educational Program (a blended learning program including online learning, practice-based seminar, and context-bound learning)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study: 16843184

Group type: EXPERIMENTAL
Intervention: Standardized (EMPIRIC) programming, n = 445
Number of subjects: 900

Group type: COMPARATOR
Intervention: Physician-tailored (TAILORED) programming, n = 455
Number of subjects: 900
Study: 12974697

Group type: EXPERIMENTAL
Intervention: S-Caine Peel (7% lidocaine and 7% tetracaine) applied for 30 or 60 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: S-Caine Peel (7% lidocaine and 7% tetracaine) applied for 60 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: S-Caine Peel (7% lidocaine and 7% tetracaine) applied for 90 minutes
Number of subjects: 100
Study: 10695627

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid and norfloxacin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 62
Study: 8977062

Group type: EXPERIMENTAL
Intervention: Contact laser vaporization prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study: 1470448

Group type: EXPERIMENTAL
Intervention: CT with contrast (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Needle aspiration (Group B)
Number of subjects: 24
Study: 6141424

Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (1000 mg/m2) in addition to conventional oral therapy of mercaptopurine and low-dose methotrexate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Methotrexate clearance
Number of subjects: 108
Study: 30413333

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery
Number of subjects: 400
Study: 29476888

Group type: EXPERIMENTAL
Intervention: DE-PLAN educational healthy lifestyle promotion programme
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1088
Study: 27743432

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplements (2 × 10^9 CFU/g each of Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplements
Number of subjects: 60
Study: 24865677

Group type: EXPERIMENTAL
Intervention: TDEN vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22967674

Group type: EXPERIMENTAL
Intervention: Augmented visual feedback using bespoke visualisation software during overground physical therapy gait training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intensity-matched and attention-matched placebo group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 45
Study: 19781665

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (standard care intervention plus 12 months of telephone counseling and tailored print materials)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard care intervention (provider counseling, nurse goal setting, and educational materials)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 266
Study: 17031485

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for diagnosing effusion in GH joints
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clinical assessment of swelling
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Kappa coefficient between clinical assessment and US
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 50
Study: 15821887

Group type: EXPERIMENTAL
Intervention: Reconstituted CMV group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Reconstituted subjects
Number of subjects: 81

Group type: COMPARATOR
Intervention: Reconstituted PcP group
Number of subjects: 81

Group type: COMPARATOR
Intervention: HIV-positive controls
Number of subjects: 81

Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 81